Disco-Tech sells spine products for $220m [p.16]

By
December 21, 2006 21:07
2 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Privately owned Israeli start-up company Disc-O-Tech Medical Technologies has agreed to sell its spine-related product assets and intellectual property rights to California-based Kyphon Inc. for $220 million. "We are pleased to be able to couple our unique technology platforms with Kyphon's strong sales channel resources to provide spine specialists with less invasive treatment options for their patients," Motti Beyar, president and chief executive officer of Disc-O-Tech said in the press statement about the deal. The companies signed two contracts for Disc-O-Tech's non-invasive spine procedures, the first for its B-Twin Expandable Spinal System used in lumbar spinal fusion procedures, and its SKy Bone Expander System for the treatment of vertebral compression fractures (VCFs). The second transaction was for Disc-O-Tech's Confidence Cement System, a putty-like, radio-opaque acrylic bone cement used in the treatment of VCFs. Under the agreement, Kyphon will pay an initial $60m. to Disc-O-Tech and another $40m. no later than February 1, on the closing of the first transaction for the acquisition of either B-Twin and SKy Bone. The remaining $120m. will be paid in three equal annual installments beginning in January 2008 for Disc-O-Tech's Confidence System assets. An additional $20m. in contingent payments may also be paid based on the development of further technologies. Kyphon said it expects the acquisitions to "significantly" hurt 2007 earnings. The transactions, excluding some items, will reduce profit by 12 to 17 cents a share but were expected to add to earnings starting in 2009. The deals are expected to close in 2007. Founded in 1998 by Lewis Pell, Motti Beyar, and Oren Globerman, Herzliya-based Disc-O-Tech offers other products in its spinal line along with its products for trauma and arthoplasty treatments. It was named the most promising Israeli Life Science startup for 2005 at last year's Israeli Technology and Life Sciences Conference hosted by Tamir Fishman & RBC Capital Markets. Disc-O-Tech declined to comment to The Jerusalem Post about the deal. Kyphon said the technologies would further extend its minimally invasive spine franchise beyond its present technologies for the treatment of vertebral compression fractures and to diagnose the source of low back pain. "Disc-O-Tech's innovative B-Twin Expandable Spinal System and related intellectual property assets will permit Kyphon to further serve the fast- growing industry segment focused on minimally invasive treatment of degenerative disc disease," said Richard Mott, president and CEO of Kyphon. "The acquired VCF products also promise to expand our capabilities to offer clinicians a broad suite of fracture management and repair options both in our established markets as well as providing opportunities to access more cost-sensitive emerging markets."

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS